|
BRPI0417302A
(pt)
|
2003-12-05 |
2007-03-06 |
Compound Therapeutics Inc |
inibidores de receptores de fator de crescimento endotelial vascular do tipo 2
|
|
AU2007325838B2
(en)
|
2006-11-22 |
2013-09-19 |
Bristol-Myers Squibb Company |
Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including IGF-IR
|
|
EP2247615B1
(en)
|
2008-02-14 |
2014-07-30 |
Bristol-Myers Squibb Company |
Targeted therapeutics based on engineered proteins that bind egfr
|
|
AR071874A1
(es)
|
2008-05-22 |
2010-07-21 |
Bristol Myers Squibb Co |
Proteinas de dominio de armazon basadas en fibronectina multivalentes
|
|
TWI496582B
(zh)
|
2008-11-24 |
2015-08-21 |
必治妥美雅史谷比公司 |
雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子
|
|
KR20130056870A
(ko)
*
|
2010-04-13 |
2013-05-30 |
메디뮨 엘엘씨 |
피브로넥틴 ⅲ형 도메인에 기초한 다량체 스캐폴드
|
|
TW201138808A
(en)
|
2010-05-03 |
2011-11-16 |
Bristol Myers Squibb Co |
Serum albumin binding molecules
|
|
EP3091028A1
(en)
|
2010-05-26 |
2016-11-09 |
Bristol-Myers Squibb Company |
Fibronectin based scaffold proteins having improved stability
|
|
EP3415528B1
(en)
|
2011-04-13 |
2021-05-26 |
Bristol-Myers Squibb Company |
Fc fusion proteins comprising novel linkers or arrangements
|
|
US20140187488A1
(en)
|
2011-05-17 |
2014-07-03 |
Bristol-Myers Squibb Company |
Methods for maintaining pegylation of polypeptides
|
|
US9347058B2
(en)
|
2011-05-17 |
2016-05-24 |
Bristol-Myers Squibb Company |
Methods for the selection of binding proteins
|
|
KR102434073B1
(ko)
|
2011-10-11 |
2022-08-18 |
비엘라 바이오, 인크. |
Cd40l 특이적 tn3 유래 스카폴드 및 이의 사용 방법
|
|
US9522951B2
(en)
|
2011-10-31 |
2016-12-20 |
Bristol-Myers Squibb Company |
Fibronectin binding domains with reduced immunogenicity
|
|
CN103906533A
(zh)
|
2011-11-07 |
2014-07-02 |
米迪缪尼有限公司 |
多特异性和多价结合蛋白及其用途
|
|
US20140314712A1
(en)
|
2011-11-08 |
2014-10-23 |
Umc Utrecht Holding B.V. |
Fusion protein comprising an interleukin 4 and interleukin
|
|
RS58801B1
(sr)
|
2012-09-13 |
2019-07-31 |
Bristol Myers Squibb Co |
Skafold domenski proteini na bazi fibronektina koji se vezuju za miostatin
|
|
US9695228B2
(en)
|
2012-11-21 |
2017-07-04 |
Janssen Biotech, Inc. |
EGFR and c-Met fibronectin type III domain binding molecules
|
|
US20150361159A1
(en)
|
2013-02-01 |
2015-12-17 |
Bristol-Myers Squibb Company |
Fibronectin based scaffold proteins
|
|
WO2014124017A1
(en)
|
2013-02-06 |
2014-08-14 |
Bristol-Myers Squibb Company |
Fibronectin type iii domain proteins with enhanced solubility
|
|
US10065987B2
(en)
|
2013-02-12 |
2018-09-04 |
Bristol-Myers Squibb Company |
High pH protein refolding methods
|
|
EP2956468B1
(en)
|
2013-02-12 |
2020-06-10 |
Bristol-Myers Squibb Company |
Tangential flow filtration based protein refolding methods
|
|
US20160152686A1
(en)
|
2013-03-13 |
2016-06-02 |
Bristol-Myers Squibb Company |
Fibronectin based scaffold domains linked to serum albumin or moiety binding thereto
|
|
ES2812208T3
(es)
|
2013-03-14 |
2021-03-16 |
Bristol Myers Squibb Co |
Combinación de un agonista de DR5 y un antagonista de anti-PD-1 y métodos de uso
|
|
US10392611B2
(en)
|
2013-05-30 |
2019-08-27 |
Duke University |
Polymer conjugates having reduced antigenicity and methods of using the same
|
|
US10364451B2
(en)
|
2013-05-30 |
2019-07-30 |
Duke University |
Polymer conjugates having reduced antigenicity and methods of using the same
|
|
US10196446B2
(en)
|
2013-10-14 |
2019-02-05 |
Janssen Biotech, Inc. |
Cysteine engineered fibronectin type III domain binding molecules
|
|
WO2015138638A1
(en)
|
2014-03-11 |
2015-09-17 |
Theraly Pharmaceuticals, Inc. |
Long acting trail receptor agonists for treatment of autoimmune diseases
|
|
SG11201607818WA
(en)
|
2014-03-20 |
2016-10-28 |
Bristol Myers Squibb Co |
Stabilized fibronectin based scaffold molecules
|
|
AU2015231170B2
(en)
|
2014-03-20 |
2019-10-03 |
Bristol-Myers Squibb Company |
Serum albumin-binding fibronectin type III domains
|
|
WO2015148269A2
(en)
*
|
2014-03-24 |
2015-10-01 |
Medimmune, Llc |
Stabilized tnfn3 scaffold proteins
|
|
NO2776305T3
(enExample)
|
2014-04-23 |
2018-01-27 |
|
|
|
CN106573961B
(zh)
*
|
2014-06-20 |
2022-01-04 |
豪夫迈·罗氏有限公司 |
基于chagasin的支架组合物、方法和应用
|
|
RU2715905C2
(ru)
|
2014-10-01 |
2020-03-04 |
МЕДИММЬЮН, ЭлЭлСи |
Способ конъюгации полипептида
|
|
WO2016086036A2
(en)
|
2014-11-25 |
2016-06-02 |
Bristol-Myers Squibb Company |
Methods and compositions for 18f-radiolabeling of biologics
|
|
JP6862348B2
(ja)
|
2015-03-12 |
2021-04-21 |
メディミューン，エルエルシー |
アルブミン融合タンパク質を精製する方法
|
|
WO2016154530A1
(en)
*
|
2015-03-26 |
2016-09-29 |
Duke University |
Targeted therapeutic agents comprising multivalent protein-biopolymer fusions
|
|
EA201792442A1
(ru)
*
|
2015-05-06 |
2018-06-29 |
Янссен Байотек, Инк. |
Биспецифические агенты, связывающие простатический специфический мембранный антиген (psma), и их применение
|
|
US11458205B2
(en)
|
2015-08-04 |
2022-10-04 |
Duke University |
Genetically encoded intrinsically disordered stealth polymers for delivery and methods of using same
|
|
US11124791B2
(en)
|
2015-09-14 |
2021-09-21 |
Arizona Board Of Regents On Behalf Of Arizona State University |
Generating recombinant affinity reagents with arrayed targets
|
|
US10766946B2
(en)
|
2015-09-23 |
2020-09-08 |
Bristol-Myers Squibb Company |
Fast-off rate serum albumin binding fibronectin type III domains
|
|
EP3353198B1
(en)
|
2015-09-23 |
2020-06-17 |
Bristol-Myers Squibb Company |
Glypican-3binding fibronectin based scafflold molecules
|
|
JP7174627B2
(ja)
|
2015-10-23 |
2022-11-17 |
ウニフェルシタイト・トゥヴェンテ |
インテグリン結合ペプチド及びその使用
|
|
US11007251B2
(en)
|
2015-12-17 |
2021-05-18 |
The Johns Hopkins University |
Ameliorating systemic sclerosis with death receptor agonists
|
|
US11752213B2
(en)
|
2015-12-21 |
2023-09-12 |
Duke University |
Surfaces having reduced non-specific binding and antigenicity
|
|
CN109195620B
(zh)
|
2016-04-07 |
2022-06-28 |
约翰霍普金斯大学 |
用死亡受体激动剂治疗胰腺炎和疼痛的组合物和方法
|
|
IL321475A
(en)
|
2016-05-06 |
2025-08-01 |
Medimmune Llc |
Bispecific binding proteins and their uses
|
|
CN105802970A
(zh)
*
|
2016-05-30 |
2016-07-27 |
东北师范大学 |
靶向沉默Gβ1的shRNA
|
|
WO2017210476A1
(en)
|
2016-06-01 |
2017-12-07 |
Duke University |
Nonfouling biosensors
|
|
WO2017210335A1
(en)
|
2016-06-01 |
2017-12-07 |
Bristol-Myers Squibb Company |
Imaging methods using 18f-radiolabeled biologics
|
|
WO2017223180A2
(en)
|
2016-06-21 |
2017-12-28 |
Janssen Biotech, Inc. |
Cysteine engineered fibronectin type iii domain binding molecules
|
|
EP3512868A4
(en)
|
2016-09-14 |
2020-04-15 |
Duke University |
NANOPARTICLES BASED ON TRIBLOCK POLYPEPTIDE FOR THE DELIVERY OF HYDROPHILIC DRUGS
|
|
KR20190064600A
(ko)
|
2016-09-23 |
2019-06-10 |
듀크 유니버시티 |
Lcst 거동을 갖는 비구조화된 비-반복적 폴리펩티드
|
|
KR102568559B1
(ko)
|
2016-12-14 |
2023-08-18 |
얀센 바이오테크 인코포레이티드 |
Cd8a-결합 섬유결합소 iii형 도메인
|
|
WO2018111978A1
(en)
|
2016-12-14 |
2018-06-21 |
Janssen Biotech, Inc. |
Cd137 binding fibronectin type iii domains
|
|
WO2018111976A1
(en)
|
2016-12-14 |
2018-06-21 |
Janssen Biotech, Inc. |
Pd-l1 binding fibronectin type iii domains
|
|
US11648200B2
(en)
|
2017-01-12 |
2023-05-16 |
Duke University |
Genetically encoded lipid-polypeptide hybrid biomaterials that exhibit temperature triggered hierarchical self-assembly
|
|
US10787499B2
(en)
*
|
2017-02-13 |
2020-09-29 |
Regents Of The University Of Minnesota |
EpCAM targeted polypeptides, conjugates thereof, and methods of use thereof
|
|
WO2018213320A1
(en)
|
2017-05-15 |
2018-11-22 |
Duke University |
Recombinant production of hybrid lipid-biopolymer materials that self-assemble and encapsulate agents
|
|
AR111963A1
(es)
|
2017-05-26 |
2019-09-04 |
Univ California |
Método y moléculas
|
|
EP3658168A4
(en)
|
2017-06-30 |
2021-07-14 |
Duke University |
ORDER AND DISORDER AS A DESIGN PRINCIPLE FOR STIMULI-RESPONDING BIOPOLYMER NETWORKS
|
|
WO2019147954A1
(en)
|
2018-01-26 |
2019-08-01 |
Duke University |
Albumin binding peptide-drug (aibiped) conjugates and methods of making and using same
|
|
US11491206B1
(en)
|
2018-02-13 |
2022-11-08 |
Duke University |
Compositions and methods for the treatment of trail-resistant cancer
|
|
US11680091B2
(en)
|
2018-02-23 |
2023-06-20 |
The University Of Chicago |
Methods and composition involving thermophilic fibronectin type III (FN3) monobodies
|
|
WO2019213150A1
(en)
|
2018-04-30 |
2019-11-07 |
Duke University |
Stimuli-responsive peg-like polymer-based drug delivery platform
|
|
PE20210320A1
(es)
|
2018-06-01 |
2021-02-16 |
Novartis Ag |
Moleculas de union contra bcma y usos de las mismas
|
|
CN110724198B
(zh)
*
|
2018-07-17 |
2023-05-26 |
上海一宸医药科技有限公司 |
长效纤连蛋白iii型结构域融合蛋白
|
|
EP3829622A4
(en)
|
2018-08-02 |
2022-05-11 |
Duke University |
DOUBLE AGONIST FUSION PROTEINS
|
|
WO2020051541A1
(en)
|
2018-09-07 |
2020-03-12 |
Duke University |
Nanoparticulate drug delivery systems
|
|
KR20210099614A
(ko)
|
2018-12-04 |
2021-08-12 |
노파르티스 아게 |
Cd3에 대한 결합 분자 및 이의 용도
|
|
EP3715376A1
(en)
|
2019-03-23 |
2020-09-30 |
Ablevia biotech GmbH |
Compound for the prevention or treatment of myasthenia gravis
|
|
US11986536B2
(en)
|
2019-03-23 |
2024-05-21 |
Ablevia Biotech Gmbh |
Compound for the sequestration of undesirable antibodies in a patient
|
|
EP3715374A1
(en)
|
2019-03-23 |
2020-09-30 |
Ablevia biotech GmbH |
Compound for the sequestration of undesirable antibodies in a patient
|
|
JP7641912B2
(ja)
|
2019-04-19 |
2025-03-07 |
シナーキン・ファーマ・ベスローテン・フエンノートシャップ |
Ｉｌ１３を含む融合タンパク質
|
|
AU2020279224B2
(en)
|
2019-05-21 |
2024-12-05 |
Novartis Ag |
Trispecific binding molecules against BCMA and uses thereof
|
|
US12037378B2
(en)
|
2019-05-21 |
2024-07-16 |
Novartis Ag |
Variant CD58 domains and uses thereof
|
|
UY38701A
(es)
|
2019-05-21 |
2020-12-31 |
Novartis Ag |
Moléculas de unión a cd19, conjugados, composiciones que las comprenden y usos de las mismas
|
|
US11512314B2
(en)
|
2019-07-12 |
2022-11-29 |
Duke University |
Amphiphilic polynucleotides
|
|
US20220380801A1
(en)
|
2019-07-15 |
2022-12-01 |
Medimmune Limited |
Tripartite systems for protein dimerization and methods of use
|
|
CN114786682B
(zh)
|
2019-10-14 |
2024-07-16 |
Aro生物疗法公司 |
结合cd71的纤维粘连蛋白iii型结构域
|
|
US11781138B2
(en)
|
2019-10-14 |
2023-10-10 |
Aro Biotherapeutics Company |
FN3 domain-siRNA conjugates and uses thereof
|
|
WO2021076543A1
(en)
|
2019-10-14 |
2021-04-22 |
Aro Biotherapeutics Company |
Epcam binding fibronectin type iii domains
|
|
CN111217903B
(zh)
*
|
2020-02-25 |
2022-11-15 |
芜湖天明生物技术有限公司 |
一种重组人纤连蛋白ⅲ1-c及其制备方法和应用
|
|
JP2023515633A
(ja)
|
2020-02-28 |
2023-04-13 |
ブリストル－マイヤーズ スクイブ カンパニー |
放射性標識されたフィブロネクチンに基づく足場および抗体ならびにそのセラノスティクス的使用
|
|
WO2021195513A1
(en)
|
2020-03-27 |
2021-09-30 |
Novartis Ag |
Bispecific combination therapy for treating proliferative diseases and autoimmune disorders
|
|
US11767353B2
(en)
|
2020-06-05 |
2023-09-26 |
Theraly Fibrosis, Inc. |
Trail compositions with reduced immunogenicity
|
|
CN111944204B
(zh)
*
|
2020-07-24 |
2022-03-08 |
南京理工大学 |
一种Fe3O4磁性细菌纤维素及其制备方法
|
|
WO2022063879A1
(en)
|
2020-09-23 |
2022-03-31 |
Ablevia Biotech Gmbh |
Compound for the sequestration of undesirable antibodies in a patient
|
|
EP4217402A1
(en)
|
2020-09-23 |
2023-08-02 |
Ablevia biotech GmbH |
Compound for the prevention or treatment of autoantibody-mediated conditions
|
|
TWI922495B
(zh)
|
2020-09-23 |
2026-04-21 |
奧地利商艾柏力維亞生技有限公司 |
用以於一患者中螯合非預期的抗ｐｅｇ抗體的化合物
|
|
KR20230074775A
(ko)
|
2020-09-23 |
2023-05-31 |
아블레비아 바이오테크 게엠베하 |
바이러스 벡터의 효능 증가를 위한 화합물
|
|
WO2022063887A1
(en)
|
2020-09-23 |
2022-03-31 |
Ablevia Biotech Gmbh |
Compound for increasing the efficacy of factor viii replacement therapy
|
|
CN116710143A
(zh)
|
2020-09-24 |
2023-09-05 |
艾柏力维亚生技有限公司 |
用于预防或治疗重症肌无力的化合物
|
|
US20250215081A1
(en)
|
2020-11-06 |
2025-07-03 |
Novartis Ag |
Anti-cd19 agent and b cell targeting agent combination therapy for treating b cell malignancies
|
|
AU2021373366A1
(en)
|
2020-11-06 |
2023-06-01 |
Novartis Ag |
Cd19 binding molecules and uses thereof
|
|
KR20240031947A
(ko)
|
2021-04-14 |
2024-03-08 |
에이알오 바이오테라퓨틱스 컴패니 |
Fn3 도메인-시르나 접합체 및 이의 용도
|
|
JP2024517610A
(ja)
|
2021-04-14 |
2024-04-23 |
アロ・バイオセラピューティクス・カンパニー |
Ｃｄ７１に結合するフィブロネクチンｉｉｉ型ドメイン
|
|
WO2023180502A1
(en)
|
2022-03-24 |
2023-09-28 |
Ablevia Biotech Gmbh |
Compound for increasing efficacy of oncolytic viruses
|
|
KR102459313B1
(ko)
*
|
2022-04-11 |
2022-10-26 |
주식회사 대영방재산업 |
내구성이 개선된 소방용 수격 흡수기
|
|
JP2026525824A
(ja)
|
2023-06-23 |
2026-08-04 |
アストラゼネカ・アクチエボラーグ |
分子スイッチ
|
|
WO2025125630A1
(en)
|
2023-12-15 |
2025-06-19 |
Medimmune Limited |
Method for bioprotac design
|